SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

29 Jan 2022 Evaluate
The sales figure stood at Rs. 1905.97 millions for the December 2021 quarter. The mentioned figure indicates a growth of about 49.56% as compared to Rs. 1274.37 millions during the year-ago period.The Company has registered profit of Rs. 271.74  millions for the quarter ended December 2021, a growth of 21.00%  over Rs. 224.57 millions millions achieved in the corresponding quarter of last year.Operating profit for the quarter ended December 2021 rose to 381.34 millions as compared to 345.42 millions of corresponding quarter ended December 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 1905.97 1274.37 49.56 4980.55 3554.75 40.11 4655.13 4419.51 5.33
Other Income 63.10 32.54 93.92 201.92 171.56 17.70 176.83 370.01 -52.21
PBIDT 381.34 345.42 10.40 1107.11 852.53 29.86 1091.43 1371.68 -20.43
Interest 9.52 6.28 51.59 27.87 36.68 -24.02 41.94 66.24 -36.68
PBDT 399.27 339.14 17.73 1106.69 815.85 35.65 1049.49 1305.44 -19.61
Depreciation 35.14 34.76 1.09 104.41 103.34 1.04 137.62 88.31 55.84
PBT 364.13 304.38 19.63 1002.28 712.51 40.67 911.87 1217.13 -25.08
TAX 92.39 79.81 15.76 266.69 146.03 82.63 236.86 293.79 -19.38
Deferred Tax -7.91 7.30 -208.36 -6.59 -5.46 20.70 11.69 -25.29 -146.22
PAT 271.74 224.57 21.00 735.59 566.48 29.85 675.01 923.34 -26.89
Equity 103.68 103.15 0.51 103.68 103.15 0.51 103.15 103.15 0.00
PBIDTM(%) 20.01 27.11 -26.19 22.23 23.98 -7.31 23.45 31.04 -24.46

Bliss GVS Pharma Share Price

268.95 -4.80 (-1.75%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×